secwatch.observer — SEC 8-K summary
======================================

Issuer:     VivoSim Labs, INC. (VIVS)
CIK:        0001497253
Form:       8-K
Filed at:   2025-04-02T23:59:59+00:00
Accession:  0000950170-25-048888
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organovo reports ~$11.3M cash, expects to meet Nasdaq listing requirements
--------------------------------------------------------------------------

- Preliminary cash and equivalents ~$11.3M as of March 31, 2025; Q4 net cash utilization ~$2.0M-$2.2M.
- Stock closed above $1.00 minimum bid since March 21, 2025; company expects to meet continued listing criteria.
- Hearings Panel granted exception until April 15, 2025 to demonstrate compliance with bid price and equity rules.
- Believes it meets $2.5M stockholders' equity after $9M upfront from FXR asset sale to Eli Lilly.
- Expects potential $5M milestone within 12 months from FXR program upon Phase 2 trial commencement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1497253/000095017025048888/0000950170-25-048888-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1497253/000095017025048888/onvo-20250402.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-048888

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer